Table 5.
Healthy eys | Glaucoma suspect eyes | Glaucoma eyes | ANOVA | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AD | ED | Total | P- Value** |
AD | ED | Total | P- Value** |
AD | ED | Total | P- Value** |
P- value*** |
|
Global RNFL (um/year) |
−0.51 (−0.7,−0.1) * |
−0.44 (−0.68,−0.01) |
−0.44 (−0.68,−0.01) * |
0.35 | −0.75 (−0.97,−0.52) * |
−0.64 (−0.74,−0.35) * |
−0.75 (−0.97,−0.52) |
0.75 | −0.94 (−1.2,−0.6) * |
−0.89 (−1.19,−0.54) |
−0.91 (−1.19,−0.52) * |
0.4 | 0.02 |
Nasal RNFL (um/year) |
−0.49 (−0.6,−0.24) * |
−0.35 (−0.51,−0.07) |
−0.42 (−0.55,−0.12) * |
0.3 | −0.59 (−0.92,−0.24) * |
−0.55 (−0.88,−0.02) * |
−0.57 (−0.91,−0.13) |
0.9 | −0.88 (−1.05,−0.61) * |
−0.91 (−1.12,−0.55) |
−0.9 −1.11,−0.57) * |
0.27 | 0.01 |
Temporal RNFL (um/year) |
−0.38 (−0.6,−0.06) * |
−0.31 (−0.41,−0.01) |
−0.34 (−0.52,−0.03) * |
0.8 | −0.56 (−0.78,−0.34) * |
−0.49 (−0.82,−0.18) * |
−0.52 (−0.81,−0.21) |
0.58 | −0.97 (−1.1,−0.46) * |
−0.99 (−1.09,−0.35) |
−0.98 (−1.09,−0.37) * |
0.81 | 0.02 |
Inferior RNFL (um/year) |
−0.41 (−0.56,−0.02) * |
−0.38 (−0.52,−0.01) |
−0.39 (−0.54,−0.01) * |
0.39 | −0.51 (−0.72,−0.19) * |
−0.57 (−0.79,−0.34) * |
−0.54 −0.74,−0.22) |
0.27 | −0.69 (−0.92,−0.42) * |
−0.71 (−1.04,−0.41) |
−0.70 (−0.89,−0.45) * |
0.64 | 0.01 |
Superior RNFL (um/year) |
−0.35 (−0.52,−0.12) * |
−0.39 (−0.61,−0.09) |
−0.37 (−0.57,−0.11) * |
0.33 | −0.58 (−0.75,−0.15) * |
−0.53 (−0.76,−0.24) * |
−0.55 (−0.76,−0.21) |
0.16 | −0.97 (−1.35,−0.54) * |
−1.05 (−1.28,−0.65) |
−1.01 (−1.29,−0.62) * |
0.38 | 0.004 |
Abbreviations: RNFL, retinal nerve fiber layer thickness.
significant slope (P-value < 0.05),
P-value evaluates differences in the mean rate of change between AD and ED eyes,
(ANOVA) P-values between “total” mean values among diagnostic groups (without respect to race).